ASTRO releases breast RT guide

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 19 No 9
Volume 19
Issue 9

ASTRO has published evidence-based guidelines to define appropriate fractionation of whole-breast irradiation.

ASTRO has published evidence-based guidelines to define appropriate fractionation of whole-breast irradiation. The guidelines state that hypofractionated whole-breast irradiation is effective for patients with early-stage breast cancer who meet certain criteria, including age 50 years and older and stage T1-2 N0 disease. Also, eligible patients will not have received chemotherapy. In addition, the radiation oncologist must be able to provide a relatively uniform delivery of the radiation dose and the ability to exclude the heart from the path of the radiation beam.

For patients who do not meet these criteria, there was not enough evidence to reach a consensus for or against the use of hypofractionated whole-breast irradiation (Int J Radiat Oncol Biol Phys online, July 15, 2010).

Articles in this issue
PSA test drives diagnosis within families
New RT journal calls for papers
Oral Bisphosphonates Not Linked to Esophageal Cancer Risk
Partnering of chemotherapy and radiation yields great response rates in H&N ca, but has not improved survival
Should radiation therapy plus hormone therapy be the new standard of care for locally advanced prostate cancer?
Zoledronic acid plus standard therapy offers anticancer effect in multiple myeloma
Ipilimumab put on fast track by FDA
Who's News
ASTRO releases breast RT guide
Research chair named after Dr. Salem
Breast Cancer Specialists Brace for FDA Word on Avastin
Influx of Funding Impels Collaborative Explorations to Study Sarcoma as Behavior Model for Other Cancers
ASTRO guideline sets standard for use of radiotherapy as palliative treatment of pain from bone metastases
Study supports earlier colon cancer screening for men, but not African Americans
Bone marrow procedures move into the 21st century
Recent Videos
Social workers and case managers may have access to institutional- or hospital-level grants that can reduce financial toxicity for patients undergoing cancer therapy.
Insurance and distance to a tertiary cancer center were 2 barriers to receiving high-quality breast cancer care, according to Rachel Greenup, MD, MPH.
Antibody-drug conjugates are effective, but strategies such as better understanding the mechanisms of action may lead to enhanced care for patients with cancer. Antibody-drug conjugates are effective, but strategies such as better understanding the mechanisms of action may lead to enhanced care for patients with cancer.
ADCs demonstrate superior efficacy vs chemotherapy but maintain a similar efficacy profile that requires multidisciplinary collaboration to optimally treat.
According to Aditya Bardia, MD, MPH, FASCO, antibody-drug conjugates are slowly replacing chemotherapy as a standard treatment for breast cancer.
Administering oral SERD-based regimens may enhance patients’ quality of life when undergoing treatment for ER-positive, HER2-negative breast cancer.
Gedatolisib-based triplet regimens may be effective among patients with prior endocrine resistance or rapid progression following frontline therapy.
Leading experts in the breast cancer field highlight the use of CDK4/6 inhibitors, antibody-drug conjugates, and other treatment modalities.
Related Content
According to Rachel Greenup, MD, MPH, some of the barriers to getting optimal treatment for breast cancer include access, insurance, and baseline understanding or knowledge.

How to Mitigate the Emotional, Logistical, and Financial Burdens of Cancer Treatment?

Tim Cortese
November 29th 2025
Article

According to Rachel Greenup, MD, MPH, some of the barriers to getting optimal treatment for breast cancer include access, insurance, and baseline understanding or knowledge.

Presenting investigators at ESMO Congress 2025 highlight findings from clinical trials assessing novel therapeutics across different disease types.

What Were the Key Presentations at ESMO 2025? Oncology Experts Discuss

Sara A. Hurvitz, MD;Xiuning Le, MD, PhD;Erica L. Mayer, MD, MPH
October 27th 2025
Podcast

Presenting investigators at ESMO Congress 2025 highlight findings from clinical trials assessing novel therapeutics across different disease types.

The FDA has approved pertuzumab-dpzb (Poherdy) as a biosimilar to pertuzumab (Perjeta) in breast cancer, based on a review of various attributes, including safety and efficacy data.

FDA Approves Pertuzumab Biosimilar in Breast Cancer Indications

Tim Cortese
November 13th 2025
Article

The FDA has approved pertuzumab-dpzb (Poherdy) as a biosimilar to pertuzumab (Perjeta) in breast cancer, based on a review of various attributes, including safety and efficacy data.

Upfront risk stratification for additional cardiovascular testing may help mitigate cardiovascular toxicities in breast cancer treatment.

Cardiovascular Considerations in Breast Cancer Treatment and Survivorship

Joseph S. Wallins, MD, MPH
September 8th 2025
Podcast

Up-front risk stratification for additional cardiovascular testing may help mitigate cardiovascular toxicities in breast cancer treatment.

How Dato-DXd and the TROPION Trials Are Transforming Solid Tumor Research

How Dato-DXd and the TROPION Trials Are Transforming Solid Tumor Research

Ariana Pelosci
November 8th 2025
Article

Dato-DXd is being assessed in numerous trials across the breast, lung, and bladder cancer spaces.

The safety profile of palazestrant plus ribociclib in a phase 1b trial was comparable with prior reports of each individual agent.

Palazestrant Combo Shows Preliminary Activity in ER+/HER2– Breast Cancer

Russ Conroy
November 6th 2025
Article

The safety profile of palazestrant plus ribociclib in a phase 1b trial was comparable to prior reports of each individual agent.